AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
- 1 October 2010
- journal article
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 10 (5) , 319-340
Abstract
Adeno-Associated Virus based vectors (rAAV) are advantageous for human gene therapy due to low inflammatory responses, lack of toxicity, natural persistence, and ability to transencapsidate the genome allowing large variations in vector biology and tropism. Over sixty clinical trials have been conducted using rAAV serotype 2 for gene delivery with a number demonstrating success in immunoprivileged sites, including the retina and the CNS. Furthermore, an increasing number of trials have been initiated utilizing other serotypes of AAV to exploit vector tropism, trafficking, and expression efficiency. While these trials have demonstrated success in safety with emerging success in clinical outcomes, one benefit has been identification of issues associated with vector administration in humans (e.g. the role of pre-existing antibody responses, loss of transgene expression in non-immunoprivileged sites, and low transgene expression levels). For these reasons, several strategies are being used to optimize rAAV vectors, ranging from addition of exogenous agents for immune evasion to optimization of the transgene cassette for enhanced therapeutic output. By far, the vast majority of approaches have focused on genetic manipulation of the viral capsid. These methods include rational mutagenesis, engineering of targeting peptides, generation of chimeric particles, library and directed evolution approaches, as well as immune evasion modifications. Overall, these modifications have created a new repertoire of AAV vectors with improved targeting, transgene expression, and immune evasion. Continued work in these areas should synergize strategies to improve capsids and transgene cassettes that will eventually lead to optimized vectors ideally suited for translational success.Keywords
This publication has 79 references indexed in Scilit:
- Adenovirus-Facilitated Nuclear Translocation of Adeno-Associated Virus Type 2Journal of Virology, 2002
- Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cellsOncogene, 2002
- Immunological Aspects of Recombinant Adeno-Associated Virus Delivery to the Mammalian BrainJournal of Virology, 2002
- Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant DiseaseJournal of Virology, 2002
- Virus Particle Explorer (VIPER), a Website for Virus Capsid Structures and Their Computational AnalysesJournal of Virology, 2001
- Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null MutationMolecular Therapy, 2001
- Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesisGene Therapy, 2001
- Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissuesInternational Journal of Cancer, 1999
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- Fluorescent erythrocyte ghosts as standards for quantitative flow cytometryCytometry, 1995